Dyne Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 2,722 | $31.89 | $86,805 | 140,612 | Sep 11, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Option Exercise | 6,502 | $5.54 | $36,021 | 117,524 | Sep 6, 2024 |
| Kersten Dirk | — | Sale | 1,577 | $35.03 | $55,242 | 398,423 | Sep 5, 2024 |
| Cox John | CEO & President | Purchase | 800 | $32.57 | $26,056 | 800 | Sep 4, 2024 |
| Kerr Douglas | Chief Medical Officer | Award / Grant | 47,500 | — | — | 47,500 | Sep 3, 2024 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Award / Grant | 58,400 | — | — | 58,400 | Sep 3, 2024 |
| Kersten Dirk | — | Sale | 6,204 | $46.01 | $285,446 | 400,000 | Aug 30, 2024 |
| Kersten Dirk | — | Sale | 10,768 | $45.81 | $493,282 | 431,300 | Aug 29, 2024 |
| Kersten Dirk | — | Sale | 11,534 | $45.79 | $528,142 | 630,964 | Aug 26, 2024 |
| Kersten Dirk | — | Sale | 413 | $46.97 | $19,399 | 805,549 | Aug 22, 2024 |
| Kersten Dirk | — | Sale | 8,326 | $47.30 | $393,820 | 1,036,633 | Aug 20, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Sale | 2,442 | $45.01 | $109,914 | 111,332 | Aug 19, 2024 |
| McNeill Jonathan | Chief Business Officer | Sale | 2,400 | $45.01 | $108,024 | 132,411 | Aug 19, 2024 |
| Farwell Wildon | Chief Medical Officer | Sale | 2,060 | $45.01 | $92,721 | 143,483 | Aug 19, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 328 | $46.00 | $15,088 | 145,882 | Aug 19, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Sale | 296 | $46.00 | $13,616 | 144,875 | Aug 19, 2024 |
| Kersten Dirk | — | Sale | 89,824 | $46.01 | $4,132,802 | 1,129,233 | Aug 19, 2024 |
| Kersten Dirk | — | Sale | 100,650 | $43.67 | $4,395,386 | 1,553,039 | Aug 15, 2024 |
| Kersten Dirk | — | Sale | 21,428 | $43.57 | $933,618 | 1,653,689 | Aug 13, 2024 |
| Kersten Dirk | — | Sale | 1,160 | $44.04 | $51,086 | 6,232,959 | Aug 9, 2024 |
| Kersten Dirk | — | Sale | 50,736 | $42.55 | $2,158,817 | 1,907,594 | Aug 8, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 29,787 | $35.01 | $1,042,843 | 148,792 | Jun 24, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Option Exercise | 10,163 | $5.54 | $56,303 | 158,955 | Jun 21, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 13,964 | $33.70 | $470,587 | 148,792 | Jun 12, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Sale | 2,136 | $31.34 | $66,942 | 147,511 | Jun 11, 2024 |
| Farwell Wildon | Chief Medical Officer | Sale | 1,628 | $31.27 | $50,908 | 146,551 | Jun 11, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 80,000 | $30.24 | $2,419,200 | 154,062 | Jun 11, 2024 |
| McNeill Jonathan | Chief Business Officer | Sale | 1,823 | $31.34 | $57,133 | 134,811 | Jun 11, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Sale | 1,590 | $30.23 | $48,066 | 115,105 | Jun 11, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Option Exercise | 30,426 | $1.03 | $31,339 | 180,073 | May 20, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Sale | 2,222 | $28.20 | $62,660 | 150,130 | May 16, 2024 |
| Farwell Wildon | Chief Medical Officer | Sale | 425 | $28.59 | $12,151 | 148,179 | May 16, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 2,249 | $28.20 | $63,422 | 154,551 | May 16, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Sale | 462 | $28.59 | $13,209 | 116,695 | May 16, 2024 |
| McNeill Jonathan | Chief Business Officer | Sale | 2,279 | $28.20 | $64,268 | 137,129 | May 16, 2024 |
| Farwell Wildon | Chief Medical Officer | Sale | 1,585 | $25.70 | $40,735 | 151,590 | Mar 12, 2024 |
| McNeill Jonathan | Chief Business Officer | Sale | 54,648 | $26.72 | $1,460,195 | 141,873 | Mar 11, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Sale | 1,590 | $24.99 | $39,734 | 119,283 | Mar 11, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Sale | 2,081 | $25.70 | $53,482 | 152,352 | Mar 11, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 291 | $27.41 | $7,976 | 159,092 | Mar 8, 2024 |
| Brumm Joshua T | CEO & President | Sale | 435 | $27.38 | $11,910 | 554,385 | Mar 8, 2024 |
| Brumm Joshua T | CEO & President | Sale | 9,086 | $25.85 | $234,873 | 554,385 | Mar 7, 2024 |
| Beskrovnaya Oxana | Chief Scientific Officer | Sale | 2,373 | $25.85 | $61,342 | 154,433 | Mar 7, 2024 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sale | 1,591 | $25.85 | $41,127 | 186,291 | Mar 7, 2024 |
| Farwell Wildon | Chief Medical Officer | Sale | 8,364 | $25.80 | $215,791 | 154,732 | Mar 7, 2024 |
| McNeill Jonathan | Chief Business Officer | Sale | 2,434 | $25.85 | $62,919 | 141,184 | Mar 7, 2024 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Sale | 2,273 | $25.85 | $58,757 | 121,955 | Mar 7, 2024 |
| Rhodes Jason P | — | Sale | 29,435 | $30.05 | $884,522 | 1,458,691 | Mar 1, 2024 |
| Atlas Venture Associates Opportunity II, LP | — | Sale | 29,435 | $30.05 | $884,522 | 1,458,691 | Mar 1, 2024 |
| Brumm Joshua T | CEO & President | Option Exercise | 5,520 | $5.54 | $30,581 | 568,991 | Mar 1, 2024 |